文献速递瓣膜外科

Mitroflow生物瓣行主动脉瓣置换术后再干预过多:一项随机试验的十年结局

Excess Reintervention With Mitroflow Prosthesis for Aortic Valve Replacement: Ten-Year Outcomes of a Randomized Trial.
PubMed 文献 · Ann Thorac Surg · 2022-09-30

2009至2011年,300例重度主动脉瓣狭窄行主动脉瓣置换的成人被随机分配接受Edwards Magna、St Jude Epic或Sorin Mitroflow生物瓣(分别为100、101、99例)。中位随访9.8年,三组10年生存率无显著差异,但Mitroflow组10年再干预风险为22%,高于Magna组的0%(P<.001)和Epic组的5%(P=.008),且Mitroflow组心内膜炎发生率高于Magna组(7% vs 0%,P=.019)。

要点

  • Mitroflow组10年再干预风险22%,高于Magna组0%(P<.001)和Epic组5%(P=.008)。
  • Mitroflow组10年心内膜炎发生率为7%,高于Magna组的0%(P=.019),组间差异P=.033。
  • 植入23 mm及以上型号时,Magna组跨瓣压差更低、指数化主动脉瓣面积更大(P<.001)。

核心结论

  • 与Magna和Epic瓣相比,Mitroflow生物瓣与再干预率增加相关,并可能有感染风险增加。
  • Magna瓣在较大植入型号下具有最低的跨瓣压差和最大的指数化主动脉瓣面积。

研究设计与样本

  • 2009年至2011年开展的随机试验,300例重度主动脉瓣狭窄行主动脉瓣置换的成人被随机分配接受Edwards Magna(100例)、St Jude Epic(101例)或Sorin Mitroflow(99例)生物瓣。
  • 采用Kaplan-Meier法和Cox比例风险模型分析总生存,所有时间-事件结局采用竞争风险分析;连续超声心动图数据按植入瓣膜尺寸分层进行纵向模型拟合。

主要发现

  • 中位随访9.8年(四分位距8.7-10.2),10年生存率Magna组50%、Epic组42%、Mitroflow组41%(P=.415)。
  • 10年卒中累积风险为9%,三组相近。
  • 植入19 mm和21 mm瓣膜的三组指数化主动脉瓣面积和平均跨瓣压差相似;植入23 mm及以上型号时,Magna组跨瓣压差更低(P<.001)、指数化主动脉瓣面积更高(P<.001)。
  • 10年心内膜炎风险组间不同(P=.033),Mitroflow组发生率高于Magna组(7% vs 0%,P=.019)。
  • Mitroflow组晚期再干预风险为22%,高于Magna组的0%(P<.001)和Epic组的5%(P=.008)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current bioprostheses are considered to have improved durability and better hemodynamic performance compared with previous designs, but there are limited comparative data on late outcomes. METHODS: From 2009 through 2011, 300 adults with severe aortic valve stenosis undergoing aortic valve replacement (AVR) were randomly assigned to receive Edwards Magna, St Jude Epic, or Sorin Mitroflow bioprostheses (n = 100, n = 101, n = 99, respectively). Overall survival was analyzed using Kaplan-Meier and Cox proportional hazards methods, whereas competing risk analysis was used for all time-to-event outcomes. Serial echocardiographic data were fitted with longitudinal models stratified by implant valve size. RESULTS: During median follow-up of 9.8 years (interquartile range, 8.7-10.2), 10-year survival was 50% for the Magna group, 42% for the Epic group, and 41% for the Mitroflow group (P = .415). Cumulative risk of stroke was 9% at 10 years, and rates were comparable for the three groups. Indexed aortic valve area and mean gradients were similar among the three groups receiving 19 mm and 21 mm valves, but in larger (23 mm or more) prostheses, gradients were lower (P < .001) and indexed aortic valve areas were higher in the Magna group (P < .001). The 10-year risk of endocarditis differed by group (P = .033), with higher incidence in the Mitroflow vs the Magna group (7% vs 0%, P = .019). Late risk of reinterventions in the Mitroflow group was 22%, compared with 0% in the Magna group (P < .001) and 5% in the Epic group (P = .008). CONCLUSIONS: The Magna valve had the lowest gradients and largest indexed aortic valve area with larger implant sizes. The Mitroflow bioprosthesis is associated with an increased rate of reintervention and possible increased risk of infection compared with Magna and Epic valves.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Cangut B, Schaff HV, Suri RM, et al. Excess Reintervention With Mitroflow Prosthesis for Aortic Valve Replacement: Ten-Year Outcomes of a Randomized Trial. Ann Thorac Surg. 2022. PMID: 36183748. doi:10.1016/j.athoracsur.2022.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。